Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in advanced basal cell carcinoma
NCT06981325Phase 2Recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Aug 2025
- Primary completion
- Oct 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in basal cell carcinoma (BCC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Objective Response Rate at six months at 6 months. Started Aug 2025; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT06981325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06981325.